Come visit Ora at booth #2131 or set up a meeting with us to learn about how we can help bring your product from concept to approval.
In this installment, we review another innovative project, exploring the progression of a product’s development, starting with the initial germination of the idea based on clinical observations.
Ora-CAC® Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA™ (OTX-DP) for Treatment of Allergic Conjunctivitis
The New Balance Reach The Beach (RTB) Relay is one of the oldest and longest running relay races in the United States.
Ocular Therapeutix™ Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
Phase 3 Allergy Program Establishes Clinical Indication Expansion Strategy of DEXTENZA™
Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases
Collaboration Allows Portola to Advance Product Candidates Outside of Core Focus
Customer Success Stories: Celebrating Your Big Wins in 2014-2015
SkQ1 is the first mitochondria-targeted antioxidant to reach clinical phase of development for an ophthalmic indication